Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDNF | P23560 | 3/20 | 0.57 |
| ▸ | PTN | P21246 | 2/20 | 0.57 |
| ▸ | MDK | P21741 | 2/20 | 0.57 |
| ▸ | F10 | P00742 | 6/20 | 0.52 |
| ▸ | SERPINC1 | P01008 | 2/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.40 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.39 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.39 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.39 |
| ▸ | FGF2 | P09038 | 2/20 | 0.38 |
| ▸ | FGF1 | P05230 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25785583 | 0.93 | BDNF (0.62) | BDNFPTNMDKF10SERPINC1 | |
| SCHEMBL14208653 | 0.93 | BDNF (0.65) | BDNFPTNMDKF10SERPINC1 | |
| SCHEMBL27097983 | 0.86 | BDNF (0.50) | BDNFPTNMDKF10SERPINC1 | |
| SCHEMBL13321922 | 0.86 | LGALS3 (0.49) | BDNFPTNMDKLGALS3LGALS1 | |
| SCHEMBL27097974 | 0.85 | BDNF (0.53) | BDNFPTNMDKF10SERPINC1 | |
| SCHEMBL27097978 | 0.85 | BDNF (0.51) | BDNFPTNMDKF10SERPINC1 | |
| SCHEMBL27097993 | 0.85 | BDNF (0.49) | BDNFPTNMDKF10SERPINC1 | |
| SCHEMBL13321926 | 0.84 | BDNF (0.61) | BDNFPTNMDKF10SERPINC1 | |
| SCHEMBL13431406 | 0.83 | BDNF (0.69) | BDNFPTNMDKF10SERPINC1 | |
| SCHEMBL16884736 | 0.81 | BDNF (0.45) | BDNFPTNMDKF10LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238328-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | GLYCOLOGIX INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-11911411-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | GLYCOLOGIX, INC. (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238328-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | MATR3, CSGALNACT1, CD44 | BDNF 1027/4885PTN 44/4885MDK 801/4885 |
| US-11911411-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | MATR3, CSGALNACT1, CD44 | BDNF 1027/4885PTN 44/4885MDK 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.